Study identifies benefits, risks linked to weight-loss drugs. WashU Medicine
The GLP-1 Megatrend (1 of 4): The Mechanistic Blind Spot No One Wants to Admit Published in Biomedical Research India Ambler and 2 others The rapid ascent of GLP-1based therapies has created one of the most consequential shifts in modern medicine, reshaping clinical practice across obesity, diabetes, cardiometabolic disease, liver pathology, and even neurodegeneration
Maternal undernutrition markedly reduces the postnatal surge of plasma leptin, which particularly disturb the hypothalamic wiring and the gene expression of the anorexigenic POMC neurons (Delahaye et al., 2004)
For practices looking to build a dedicated weight loss program around these services, this guide on starting a weight loss clinic is a helpful next step
Jimena Hathaway, MD, MPH, published in the Journal of the American Medical Association, indicates that Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, shows an increased risk of vision loss
Patients experiencing these symptoms should discontinue their GLP-1 medication immediately and seek urgent medical evaluation
